Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PharmaCyte up 10% on positive biocompatibility study results for CypCaps
Sep. 16, 2021 9:56 AM ETPharmaCyte Biotech, Inc. (PMCB)By: Jonathan M Block, SA News Editor
Laboratory
nicolas_/E+ via Getty Images
Shares of PharmaCyte Biotech (NASDAQ:PMCB) are up 10% in morning trading as the company announced positive test results on biocompatibility studies of its CypCaps cellulose sulphate capsules.
Results showed that the capsule material does not activate the body’s the complement system, which is involved in immune and inflammatory responses.
PharmaCyte uses its proprietary live-cell encapsulation technology, Cell-in-a-Box, which involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.
Last month, the company said it would expand its product pipeline to include diabetes and malignant ascites programs.
Read: PharmaCyte expands product pipeline to include diabetes and malignant ascites
NBC host Jim Cramer has once again advised investors to avoid buying shares in Chinese electric vehicle maker Nio Inc. (NYSE:NIO).
What Happened: “Pass, pass, hard pass. Going elsewhere. We’re not fooling around anymore,” Cramer said on CNBC’s “Mad Money Lightning Round” on Wednesday.
Cramer had previously advised investors in July to sell their shares in Nio, seen as a Tesla Inc. (NASDAQ:TSLA) rival, as he was “very worried” about the regulatory crackdown in China.
Why It Matters: Nio’s shares are down 43% from their 52-week high of $66.99 reached in January and also down almost 22% for the year-to-date period.
PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology. Our partner ( the creator of CELL IN THE BOX Austrianova/SG Austria announced that after extensive due diligence Real Tech Fund (Japan) has invested an undisclosed seven figure amount in Austrianova.Austrianova Secures $100 Million USD Investment Commitment from GEM as Company Seeks to Go Public.
PMCB has just raised 90 million dollars to move forward with their treatment and trial.
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA). It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, while at the same time, proving that PharmaCyte has what is considered the “Holy Grail” for diabetes—an encapsulation technology that can live inside the human body and protect the cells inside from the body’s own immune response.
PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®, is a one-of-a-kind cell encapsulation technology, and its planned clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC, could very well attract a lot of attention from companies, organizations and investors in both the cancer and diabetes spaces.
What makes this cell encapsulation different than others that have been tried? For the treatment of cancer, PharmaCyte’s Cell-in-a-Box® technology is made up of tiny pinhead-sized porous capsules that contain about 20,000 live cells. Unlike many other encapsulation materials, the Cell-in-a-Box® technology offers the following advantages for developing a therapy that will live inside the human body.
Capsules are made of bio-inert material and are biocompatible
Capsules have been proven to be safe, effective and durable inside the human body
Capsules do not elicit immune responses or damage surrounding tissues
Capsules have pores for nutrient and waste transfer
Pores are too small for immune system cells to enter or encapsulated live cells to leave
Manageable logistics and long shelf life
Other encapsulation materials – such as alginate – are less robust and stable. The others break down in a relatively short period of time in the body, allowing the immune system cells to destroy the cells inside of the capsules
None of the others can effectively freeze live cells to ship them to anywhere in the world and then be thawed with approximately 95% viability of the encapsulated live cells
PharmaCyte’s pancreatic cancer candidate is a “targeted chemotherapy” treatment that has proven itself effective and safe to use in past clinical trials. It’s a therapy that has shown little to no treatment-related side effects, and it could significantly reduce tumor size. Chemotherapy with little to no side effects is unheard of in the cancer arena, and, if PharmaCyte is successful in FDA clinical trials, this treatment could truly change the way that patients with solid tumors are treated well into the future.
When given the go-ahead by the FDA to enter a clinical trial after PharmaCyte submits its Investigational New Drug application (IND), it will be the company’s pancreatic cancer treatment that is under the watchful eye of the FDA, but let’s be honest—it is the company’s live-cell encapsulation technology that is truly on trial in the court of public opinion when it comes to future possibilities for Cell-in-a-Box® and its potential applications for solid cancerous tumors and diabetes.
Why would there be so much interest in a “targeted chemotherapy” treatment with little to no treatment-related side effects or in a live-cell encapsulation technology that can survive inside the human body without being attacked by the body’s own immune system cells? Well, sadly it really is all about money. Undoubtedly a better treatment for patients who suffer from LAPC is long overdue; however, developing treatments for other solid cancerous tumors and diabetes are far more lucrative.
Numbers don’t lie and as of 2016, $827-billion are spent annually in the treatment of diabetes worldwide. This is a staggering number, but it certainly sheds some light on why a treatment for diabetes that doesn’t include monitoring glucose levels, diabetics sticking their fingers many times a day, wearing insulin pumps, etc. is being sought by many companies, organizations and universities.
And this is just diabetes. There are many cancers that a therapy like PharmaCyte’s could potentially be developed for as well, including ovarian, liver, breast, and colon.
In a press release, PharmaCyte’s CEO stated that the possibility exists that if the data produced in a planned clinical trial from PharmaCyte’s therapy are significantly better than the data from the comparator arm(s), this may allow PharmaCyte to apply to the FDA for accelerated approval. It is this data along with the survivability of the capsules and the cells inside the capsules that many will be waiting to see. Accelerated approval could be accomplished if PharmaCyte applies for and receives approval for either the Breakthrough Therapy designation or the Fast Track designation.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply as close as possible to the site of the patient’s tumor.
Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at about one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted, and when the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer.
Meanwhile, PharmaCyte already has a diabetes candidate as well. Its therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body and/or beta islet cells. The encapsulation for this therapy is also done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they function as a “bio-artificial pancreas” for purposes of insulin production. Additionally, PharmaCyte says it plans to explore the encapsulation of beta islet cells as an alternative to using genetically modified human cells.
The path forward is clear, and there really is only one thing left to do. PharmaCyte must get the FDA’s approval to begin a clinical trial for the treatment of LAPC, and then use that trial as an opportunity to prove to its shareholders and to those in both the biotechnology and pharmaceutical sectors that are developing treatments for cancer and diabetes that this one-of-a-kind cell encapsulation technology can dramatically change the way that these two diseases are treated.
It would be great if PMCB could or would be able to do that BUT that is not what PMCB is working on. Take a look at what PMCB is working on:
Live Cell Encapsulation Technology
The Cell-in-a-Box® live cell encapsulation technology employed by PharmaCyte is a “platform” upon which treatments for different diseases may be built. This technology encloses live cells in protective “capsules” about the size of the head of a pin. The capsules are designed to allow blood to enter and nourish the living cells inside them. The live cells thrive while the capsules are in the body. But the capsules are also designed to protect the live cells from attack by the body’s immune system. The live cells are too large to escape from the capsules, and the body’s immune system cells are too large to enter the capsules and destroy them. PharmaCyte is using this technology to develop unique therapies for various forms of cancer and for Type 1 diabetes and insulin dependent Type 2 diabetes.
I put a juicy bid for 100,000@.6161 shares of AEZS and nobody wants to hit so I would say hit my bid or this is the bottom. Good luck
Well I took in a chunk of shares today @ .64 lets see where this takes us. Last time we took a position in AEZS it was for the Jan effect and the price was in the .40 range. It paid off big time ran to over $3.00. Lets see what happens here in the next couple of days.
looking like its time to buy AEZS
We have plenty of funds to move forward and fund our trial....
As of September 13, 2021, the Company had cash on hand of approximately $88 million.
PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology. Our partner ( the creator of CELL IN THE BOX Austrianova/SG Austria announced that after extensive due diligence Real Tech Fund (Japan) has invested an undisclosed seven figure amount in Austrianova.Austrianova Secures $100 Million USD Investment Commitment from GEM as Company Seeks to Go Public.
PMCB has just raised 90 million dollars to move forward with their treatment and trial.
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA). It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, while at the same time, proving that PharmaCyte has what is considered the “Holy Grail” for diabetes—an encapsulation technology that can live inside the human body and protect the cells inside from the body’s own immune response.
PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®, is a one-of-a-kind cell encapsulation technology, and its planned clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC, could very well attract a lot of attention from companies, organizations and investors in both the cancer and diabetes spaces.
What makes this cell encapsulation different than others that have been tried? For the treatment of cancer, PharmaCyte’s Cell-in-a-Box® technology is made up of tiny pinhead-sized porous capsules that contain about 20,000 live cells. Unlike many other encapsulation materials, the Cell-in-a-Box® technology offers the following advantages for developing a therapy that will live inside the human body.
Capsules are made of bio-inert material and are biocompatible
Capsules have been proven to be safe, effective and durable inside the human body
Capsules do not elicit immune responses or damage surrounding tissues
Capsules have pores for nutrient and waste transfer
Pores are too small for immune system cells to enter or encapsulated live cells to leave
Manageable logistics and long shelf life
Other encapsulation materials – such as alginate – are less robust and stable. The others break down in a relatively short period of time in the body, allowing the immune system cells to destroy the cells inside of the capsules
None of the others can effectively freeze live cells to ship them to anywhere in the world and then be thawed with approximately 95% viability of the encapsulated live cells
PharmaCyte’s pancreatic cancer candidate is a “targeted chemotherapy” treatment that has proven itself effective and safe to use in past clinical trials. It’s a therapy that has shown little to no treatment-related side effects, and it could significantly reduce tumor size. Chemotherapy with little to no side effects is unheard of in the cancer arena, and, if PharmaCyte is successful in FDA clinical trials, this treatment could truly change the way that patients with solid tumors are treated well into the future.
When given the go-ahead by the FDA to enter a clinical trial after PharmaCyte submits its Investigational New Drug application (IND), it will be the company’s pancreatic cancer treatment that is under the watchful eye of the FDA, but let’s be honest—it is the company’s live-cell encapsulation technology that is truly on trial in the court of public opinion when it comes to future possibilities for Cell-in-a-Box® and its potential applications for solid cancerous tumors and diabetes.
Why would there be so much interest in a “targeted chemotherapy” treatment with little to no treatment-related side effects or in a live-cell encapsulation technology that can survive inside the human body without being attacked by the body’s own immune system cells? Well, sadly it really is all about money. Undoubtedly a better treatment for patients who suffer from LAPC is long overdue; however, developing treatments for other solid cancerous tumors and diabetes are far more lucrative.
Numbers don’t lie and as of 2016, $827-billion are spent annually in the treatment of diabetes worldwide. This is a staggering number, but it certainly sheds some light on why a treatment for diabetes that doesn’t include monitoring glucose levels, diabetics sticking their fingers many times a day, wearing insulin pumps, etc. is being sought by many companies, organizations and universities.
And this is just diabetes. There are many cancers that a therapy like PharmaCyte’s could potentially be developed for as well, including ovarian, liver, breast, and colon.
In a press release, PharmaCyte’s CEO stated that the possibility exists that if the data produced in a planned clinical trial from PharmaCyte’s therapy are significantly better than the data from the comparator arm(s), this may allow PharmaCyte to apply to the FDA for accelerated approval. It is this data along with the survivability of the capsules and the cells inside the capsules that many will be waiting to see. Accelerated approval could be accomplished if PharmaCyte applies for and receives approval for either the Breakthrough Therapy designation or the Fast Track designation.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply as close as possible to the site of the patient’s tumor.
Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at about one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted, and when the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer.
Meanwhile, PharmaCyte already has a diabetes candidate as well. Its therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body and/or beta islet cells. The encapsulation for this therapy is also done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they function as a “bio-artificial pancreas” for purposes of insulin production. Additionally, PharmaCyte says it plans to explore the encapsulation of beta islet cells as an alternative to using genetically modified human cells.
The path forward is clear, and there really is only one thing left to do. PharmaCyte must get the FDA’s approval to begin a clinical trial for the treatment of LAPC, and then use that trial as an opportunity to prove to its shareholders and to those in both the biotechnology and pharmaceutical sectors that are developing treatments for cancer and diabetes that this one-of-a-kind cell encapsulation technology can dramatically change the way that these two diseases are treated.
This bolds well for PMCB and the Diabetes part of our co. Our competition seems to be having problems (We Knew that our encapsulation medium was superior and well above theirs)Ours is cellulose and theirs is that aliginate that cant be frozen or stored-
PMCB's will hold up to time and can be frozen and shipped around the world other cant
Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia.Timothy Kieffer, Ph.D., will join the clinical-stage regenerative medicine biotech as CSO, the company said Monday. He replaces Kevin D’Amour, Ph.D., who left ViaCyte in June to “pursue other opportunities.” Vice President of Translation Research Evert Kroon, Ph.D., served in the CSO role on an interim basis.The CSO appointment follows a shuffle in ViaCyte’s management earlier this year, that saw the CEO, chief operating officer and chief technology officer roles change hands. Michael Yang, formerly of Johnson & Johnson unit Janssen and Acadia, was named CEO and president in January.Kieffer comes from the University of British Columbia where he oversaw the molecular and cellular medicine lab focusing on cell therapy and novel gene approaches to treat diabetes. Kieffer co-founded enGene, a biotech developing non-viral gene therapies for mucosal tissue.RELATED: ViaCyte extends series D by $45M one day after losing its chief scientific officerSan Diego-based ViaCyte is developing cell replacement therapies to address diseases like Type 1 diabetes. The biotech's candidates target glucose control to reduce the risk of hypoglycemia and other diabetes-related complications. The technology stems from pluripotent stem cells, which can create any type of cell or tissue needed by the body for repair.Kieffer will lead ViaCyte's team focusing on these diabetes interventions.ViaCyte signed a gene-editing partnership with CRISPR Therapeutics in 2018 worth $10 million upfront with an additional $10 million down the line.
Diabetes
Diabetes is caused by insufficient availability of, or resistance to, insulin. Insulin is produced by the islet cells of the pancreas. Its function is to assist in the transport of sugar in the blood to the inside of most types of cells in the body where it is used as a source of energy for those cells. In Type 1 diabetes the islet cells of the pancreas have been destroyed – usually by an autoimmune reaction. Type 1 diabetics require daily insulin administration through injection or through the use of an insulin pump. In Type 2 diabetes the body does not use insulin properly. This means the body has become resistant to insulin. Type 2 diabetes can generally be controlled by diet and exercise in its early stages. As time goes by, it may be necessary to use antidiabetic drugs to control the disease. However, over time these too may lose their effectiveness. Thus, even Type 2 diabetics may become insulin-dependent.
Efforts to Cure Diabetes
In an effort to “cure” Type 1 diabetes, replacement of damaged pancreatic islet cells has been attempted. This involves transplantation of the entire pancreas or of its beta islet insulin-producing cells. In 2000, islet cells from human cadavers were transplanted into 7 insulin-dependent diabetics in a clinical trial carried out in Edmonton, Canada. The procedure was known as the “Edmonton Protocol.” Each patient enrolled remained insulin-independent for one year. But because of the high doses of immune-suppressive drugs that must accompany such transplantations, patients were placed at high risk of infection and even cancer. These drugs have serious side effects and have required patients to cease treatment with them. Worldwide, less than 1,000 people with Type 1 diabetes are known to have been transplanted with pancreatic islets from another human.
Attempts to avoid the use of islet cells from human donors have led to islet cells from pigs being used. This type of interspecies transplantation is known as xenotransplantation. Drug regulatory authorities have shown resistance in approving the use of such interspecies transplantations. In addition, there are problems besides regulatory approval, the foremost of which is an attack by the body’s immune system on the transplanted cells. To protect the non-human cells from attack by the immune system of the human being, they have been encapsulated using other forms of encapsulation technology than we use. In those studies, the transplanted islet cells from pigs were surrounded by a capsule typically made of alginate (a derivative of seaweed).
However, to translate this concept into a viable treatment for Type 1 diabetes, researcher’s efforts have been plagued by poor survival of the transplanted islet cells. In addition, the integrity of capsules composed of alginate has been shown to degrade over time. This then allows for immune system attack on the transplanted pig islets and necessitates additional transplantations. Also, as the alginate “capsules” degrade, they can elicit an immune response.
Different tubular and planar “chamber-type” immune-protective devices that contain islet cells are under development by other companies. These devices are placed in the body where they can be retrieved and replaced when necessary. Tubular chambers have shown good biocompatibility, but they are subject to rupture, exposing the islets to immune system attack. They also require large numbers of islet cells. Planar chambers are more stable, but they can cause extensive foreign body reactions in the host resulting in fibrotic overgrowth and thus transplant failure.
The most extensively researched immune-protective strategy is that which employs microcapsules. They are relatively simple to manufacture, can be implanted into the body without major surgery, and, depending on the nature of the encapsulation material, micro-encapsulated cells can be cryopreserved. Micro-encapsulated islet cells first made their appearance in 1994 when a diabetic patient, already receiving immunosuppressive drugs, was transplanted with these cells encapsulated in alginate and remained insulin-independent for 9 months. However, 22 years and numerous clinical trials later, there are still no reports of long-term insulin-independence in non-immune-suppressed diabetic patients receiving encapsulated pancreatic islet transplants.
Bio-Artificial Pancreas for Diabetes
We plan to develop a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Our therapy involves encapsulation of human cells that have been genetically engineered to produce, store insulin and release insulin on demand at levels in proportion to the levels of blood sugar (glucose) in the human body. We also plan to explore the encapsulation of human stem cells as an alternative to using genetically modified human liver cells. The encapsulation will be done using the Cell-in-a-Box® technology.
Until the FDA allows PharmaCyte to commence the clinical trial involving LAPC described in our recently filed IND for which the FDA has placed a clinical hold, we are not spending any further resources developing this program. However, related work on the Melligen cells continues at UTS.
Insulin-producing cells (HIT-T15) have already been encapsulated using the sodium cellulose sulfate-based technology found in Cell-in-a-Box®. Encapsulation did not affect cell viability or insulin production. In cell culture, the encapsulated cells were able to detect the glucose concentration in a nutrient solution and react in a proper way by producing insulin. In the opinion of the authors of the study, encapsulation of insulin-producing cells with sodium cellulose sulfate, which is more biocompatible and less immunogenic than other encapsulation materials, seemed to be a promising method for the immunoisolation of porcine beta islet cells for xenotransplantation to replace the endocrine pancreas. Schaffellner S., et al.
Transplantation Proc., Vol. 37, 248-252 (2005)
In an effort to avoid the use of non-human islet cells in its diabetes treatment, PharmaCyte has obtained from the University of Technology Sydney (“UTS”) in Australia an exclusive, worldwide license to use insulin-producing genetically engineered human liver cells developed by UTS to treat Type 1 diabetes and insulin-dependent Type 2 diabetes. These cells, named “Melligen,” have already been tested in mice and shown to produce insulin in direct proportion to the amount of glucose in their surroundings. In fact, when Melligen cells were transplanted into immosuppressed diabetic mice, their blood glucose levels became normal. The Melligen cells reversed the diabetic condition.
Melligen cells can be readily grown in culture and are available in unlimited supply. Compared to native pancreatic beta islet cells, Melligen cells are much more resistant to the pro-inflammatory cytokines that have been shown to be involved in beta islet cell death. We believe that this property makes them an ideal potential candidate cell line for beta islet cell replacement therapy with the prospect to achieve long-term transplant graft function. However, further research and development (“R&D”) needs to be done with the Melligen cells to ensure they function as reported in the literature by UTS.
PharmaCyte has acquired from Austrianova an exclusive, worldwide license to use the Cell-in-a-Box® technology for the development of a treatment for diabetes. We believe that encapsulating the Melligen cells using Cell-in-a-Box® live-cell encapsulation technology has numerous advantages over encapsulation of cells with other materials, such as alginate. Since our capsules are composed largely of cellulose (a bio-inert material in the human body), the Cell-in-a-Box® capsules are durable, resilient and long-lasting when compared to the competition. They remain intact for long periods of time in the body, all the while protecting the cells inside them from immune system attack. Also, in prior studies these capsules and the cells inside them have not caused any immune or inflammatory responses like those seen with alginate-encapsulated cells. Studies have shown that the Cell-in-a-Box encapsulation process does not reduce the capability of the Melligen cells to produce insulin.
We believe that the combination of the Melligen cells and the Cell-in-a-Box® encapsulation technology could lead to a breakthrough therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Encapsulating the Melligen cells could enable us to overcome all of the past problems in developing a true bio-artificial pancreas. Members of our International Diabetes Consortium (see under “Company” tab), are working in concert to develop our therapy for insulin-dependent diabetes.
Its easy to understand why the price keeps going lower. Its all about the COVID and bad management. Will they have the funds to stay open? Not many are wanting to fly there. I dont blame them
my friend lives there and tried to get a flight with them and they couldnt give him a solid time or flight. So sad
Are they still flying or have they been grounded?
The first-ever blood test for pancreatic cancer This could be a big win for PMCB (pancreatic adenocarcinoma) is now available for people considered high risk for the disease due to family history or genetic alterations.
Immunovia Inc.'s IMMray® PanCan-d test can potentially detect pancreatic cancer before it causes symptoms or is diagnosed through other methods. The test does not provide a definitive diagnosis and is not a standalone indicator of the presence of pancreatic cancer.
Read more about Immunovia Inc.'s IMMray PanCan-d Test.
PanCAN Patient Services is here to provide free information and answer questions about the blood test, as well as discuss other ways to detect and diagnose pancreatic cancer.
Diagnosing pancreatic cancer in its earlier stages can lead to more treatment options, including surgery, and better survival.
PanCAN is working on progress in early detection research, including our Early Detection Initiative, announced in April this year. Immunovia Inc.'s IMMray PanCan-d test can be another important step toward more patients being diagnosed earlier.
If you are considered high risk for developing pancreatic cancer, contact PanCAN Patient Services regarding next steps, including speaking with your doctor about whether the new blood test may be right for you.
Nio has been a great short for us. Its been down 35% this yr. Looking for the high 20's for the bleeding of price to stop
Nio Inc ADR (NIO)
37.40 -0.58 (-1.53%) 10:40 ET [NYSE]
37.39 x 31 37.41 x 800 REALTIME by
BARCHART OPINION for Mon, Sep 13th,
Overall Average:
88% SELL
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
Barchart Opinion
INDICATOR
Opinion Strength & Direction
Composite Indicator
TrendSpotter
SELL
Short Term Indicators
20 Day Moving Average
SELL
20 - 50 Day MACD Oscillator
SELL
20 - 100 Day MACD Oscillator
SELL
20 - 200 Day MACD Oscillator
SELL
20 - Day Average Volume: 40,577,688 Average: 100% SELL
Medium Term Indicators
50 Day Moving Average
SELL
50 - 100 Day MACD Oscillator
BUY
50 - 150 Day MACD Oscillator
SELL
50 - 200 Day MACD Oscillator
SELL
50 - Day Average Volume: 49,013,504 Average: 50% SELL
Long Term Indicators
100 Day Moving Average
SELL
150 Day Moving Average
SELL
200 Day Moving Average
SELL
100 - 200 Day MACD Oscillator
SELL
100 - Day Average Volume: 59,093,395 Average: 100% SELL
Looking for Barchart Legacy Opinions? Click Here.
This is a crash and burn scam. Could bankrupcty happen soon?
88% SELL UGLY
Thai Airways Intl (TAWNF)
0.0900 -0.0001 (-0.11%) 09:59 ET [OTC US]
BARCHART OPINION for Mon, Sep 13th,
Overall Average:
88% SELL
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
TAWNF - Thai Airways Intl Stock Barchart Opinion - Barchart.com
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing product stability testing required by the U.S. Food and Drug Administration (FDA). This means that the product has a shelf life of at least 18 months when stored at -80oC. The next scheduled timepoint in the ongoing testing will be after 2 years of storage at -80oC.
watch this close lol- could we see 6.00 after hours lol who knows nobody thought we would see 4.300 pre mkt on huge volume. 5.00 easy on the placement price. Any good news from the FDA and boom we hit 20.00. the o/s are locked up after todays volume.$$$$$$$$$$$$$$$$$$$$
It is time to reach and grab all the shares you can at this cheap price. Do the math cash per share. $$$$$
Dont be surprised to see $5.00 and higher very soon. Remember the big money paid &5.00 and the big money will always support their investments, thats just the way it is .................power hr is here
What a great day so far- We had an early golf tee time so I was up early and saw the action on PMCB lol a full point on the shares I bot yesterday under 3.20. for those that dont know the volume was huge for pre mkt so we sold them the 25k shares up a buck and then got picked up to play golf. I had told my guys to set a buy at the gap price from yesterday after hrs @3.55 and we got filled right there at the lows. Now I come back after golf and see we got a major move up again. LOL This is really the perfect storm.. PMCB can see $20..00 by months end.$$$$$$$$$$ the stk traded the O/S 5 times over today. That to me says a huge position was taken and at a great price imo. Have a great day.............
PMCB all over the ticker tape this morning up 20% and has traded over 2 million shares already at 6am. Looks like the shares I bought yesterday and posted it real time have paid paid paid lol .Have a great day...............
Joep please feel free to post your opinion and any DD you find on PMCB. Welcome to the board. To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer
Come on PMCB start to make the run I am fully loaded with shares.... I want the Count to make me a brand new Chopper with CELL IN THE BOX as the gas tank...lol
Carl did and it was tough for some in the beginning. Look at Steve and Janice they poured their heart and soul into the start of this Company. From the start up to where it is now is just an amazing story. The best thing is if I want some cash to buy a car or anything I just sell 1000 shares of CELH it keeps going higher and higher lol. Have a great day and look at the other company I post on.
Could see $10.00 by the end of the month or sooner. Time to buy is when its getting hit. I just bought more today. Buy the dips and sell the rips. 75 million in the bank dont be surprised to see the next move it will be a big one.$$$$$$$$$$$$$$$$$$$$$$$$$$
Fantastic for sure lol. What a great short this was from 41.40 it just took one day to watch this fall 8%. locked in the profits with some options now lets see what happens. Either way we just made 8% in hours if it goes up we make the money on the calls and if it goes down further we clean up on the hedge. This was easy money and Wall street doesnt give gifts this easy lol. Have a great day..$$$$$$$$$$$$$$$$$$$$ most wont post their trades real time but I did and learn from it.
LAGUNA HILLS, Calif. --(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021 .
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner , who will deliver a presentation about PharmaCyte and participate in virtual meetings with institutional investors throughout the conference, said, “We are extremely honored to present at H.C. Wainwright’s 23rd Annual Global Investment Conference . PharmaCyte is forever grateful to H.C. Wainwright for bringing institutional investors to our door so that we could present our story in two separate capital raises that generated about $90 million .”
Mr. Waggoner continued, “For the first time in PharmaCyte’s history, we have the opportunity to develop treatments for cancer, diabetes, and malignant ascites fluid without being constrained by finances or the need to raise additional capital. We owe that to H.C. Wainwright and its institutional clients. Presenting at the firm’s Global Investment Conference gives PharmaCyte a platform to continue to tell our story and drive attention to the work we’re doing in developing treatments for hard-to-treat diseases.”
Mr. Waggoner’s presentation will provide an overview of the Company’s business. It will be available on-demand through the H.C. Wainwright portal beginning on Monday, September 13, 2021 , at 7:00 a.m. EDT .
Wow NIO I didnt know it would be this easy Perfect timing on the shorts today. Let see how fast we can see 37.00???
https://seekingalpha.com/article/4451013-pharmacyte-biotech-buy-the-dump?mail_subject=pmcb-pharmacyte-biotech-buy-the-dump&utm_campaign=rta-stock-article&utm_content=link-2&utm_medium=email&utm_source=seeking_alpha
Anthony Cataldo
6.64K Followers
PharmaCyte Biotech: Buy The 'Dump'
"I recommend that you nibble a few shares of PharmaCyte Biotech
"If the investment community can be convinced that the PharmaCyte drug pipeline shows promise, it is not inconceivable that a large pharmaceutical may exhibit some interest - preferably financial interest or partnering interest. This could be very rewarding to shareholders choosing to enter at current PPS levels. I am willing to accept the risk/reward, at least for a few quarters and until I can re-evaluate the firm's cash burn and fundamentals."
PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology. Our partner ( the creator of CELL IN THE BOX Austrianova/SG Austria announced that after extensive due diligence Real Tech Fund (Japan) has invested an undisclosed seven figure amount in Austrianova.Austrianova Secures $100 Million USD Investment Commitment from GEM as Company Seeks to Go Public
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA). It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, while at the same time, proving that PharmaCyte has what is considered the “Holy Grail” for diabetes—an encapsulation technology that can live inside the human body and protect the cells inside from the body’s own immune response.
PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®, is a one-of-a-kind cell encapsulation technology, and its planned clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC, could very well attract a lot of attention from companies, organizations and investors in both the cancer and diabetes spaces.
What makes this cell encapsulation different than others that have been tried? For the treatment of cancer, PharmaCyte’s Cell-in-a-Box® technology is made up of tiny pinhead-sized porous capsules that contain about 20,000 live cells. Unlike many other encapsulation materials, the Cell-in-a-Box® technology offers the following advantages for developing a therapy that will live inside the human body.
Capsules are made of bio-inert material and are biocompatible
Capsules have been proven to be safe, effective and durable inside the human body
Capsules do not elicit immune responses or damage surrounding tissues
Capsules have pores for nutrient and waste transfer
Pores are too small for immune system cells to enter or encapsulated live cells to leave
Manageable logistics and long shelf life
Other encapsulation materials – such as alginate – are less robust and stable. The others break down in a relatively short period of time in the body, allowing the immune system cells to destroy the cells inside of the capsules
None of the others can effectively freeze live cells to ship them to anywhere in the world and then be thawed with approximately 95% viability of the encapsulated live cells
PharmaCyte’s pancreatic cancer candidate is a “targeted chemotherapy” treatment that has proven itself effective and safe to use in past clinical trials. It’s a therapy that has shown little to no treatment-related side effects, and it could significantly reduce tumor size. Chemotherapy with little to no side effects is unheard of in the cancer arena, and, if PharmaCyte is successful in FDA clinical trials, this treatment could truly change the way that patients with solid tumors are treated well into the future.
When given the go-ahead by the FDA to enter a clinical trial after PharmaCyte submits its Investigational New Drug application (IND), it will be the company’s pancreatic cancer treatment that is under the watchful eye of the FDA, but let’s be honest—it is the company’s live-cell encapsulation technology that is truly on trial in the court of public opinion when it comes to future possibilities for Cell-in-a-Box® and its potential applications for solid cancerous tumors and diabetes.
Why would there be so much interest in a “targeted chemotherapy” treatment with little to no treatment-related side effects or in a live-cell encapsulation technology that can survive inside the human body without being attacked by the body’s own immune system cells? Well, sadly it really is all about money. Undoubtedly a better treatment for patients who suffer from LAPC is long overdue; however, developing treatments for other solid cancerous tumors and diabetes are far more lucrative.
Numbers don’t lie and as of 2016, $827-billion are spent annually in the treatment of diabetes worldwide. This is a staggering number, but it certainly sheds some light on why a treatment for diabetes that doesn’t include monitoring glucose levels, diabetics sticking their fingers many times a day, wearing insulin pumps, etc. is being sought by many companies, organizations and universities.
And this is just diabetes. There are many cancers that a therapy like PharmaCyte’s could potentially be developed for as well, including ovarian, liver, breast, and colon.
In a press release, PharmaCyte’s CEO stated that the possibility exists that if the data produced in a planned clinical trial from PharmaCyte’s therapy are significantly better than the data from the comparator arm(s), this may allow PharmaCyte to apply to the FDA for accelerated approval. It is this data along with the survivability of the capsules and the cells inside the capsules that many will be waiting to see. Accelerated approval could be accomplished if PharmaCyte applies for and receives approval for either the Breakthrough Therapy designation or the Fast Track designation.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply as close as possible to the site of the patient’s tumor.
Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at about one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted, and when the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer.
Meanwhile, PharmaCyte already has a diabetes candidate as well. Its therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body and/or beta islet cells. The encapsulation for this therapy is also done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they function as a “bio-artificial pancreas” for purposes of insulin production. Additionally, PharmaCyte says it plans to explore the encapsulation of beta islet cells as an alternative to using genetically modified human cells.
The path forward is clear, and there really is only one thing left to do. PharmaCyte must get the FDA’s approval to begin a clinical trial for the treatment of LAPC, and then use that trial as an opportunity to prove to its shareholders and to those in both the biotechnology and pharmaceutical sectors that are developing treatments for cancer and diabetes that this one-of-a-kind cell encapsulation technology can dramatically change the way that these two diseases are treated.
Got to love CELH love the product and love the huge amount of money it has made me. My wife didnt want me to name the New ship CELSIUS but the frig is always stocked with all the flavors. Thank you John and the crew for working so hard to make CELH the best new drink . It took 10 yrs but who cares its a great product.
This is very good news for the FDA and what they want :- PharmaCyte (PMCB) said Tuesday it completed an 18-month period of ongoing stability testing for its clinical trial product CypCaps as mandated by the US Food and Drug Administration.
"CypCaps remains stable and active at 18 months after completing the 18-month timepoint of ongoing product stability testing required," the biotechnology company said in a statement.
This means that the product has a minimum shelf life of 18 months when stored at minus 80 degrees Celsius, PharmaCyte said, adding that the next timepoint in the testing phase will be after two years of storage at the same temperature.
We got some great shorts off today near the highs. Looking for a downgrade coming for NIO. We are looking for 37.00 short term and then we will decide either to cover or short more if the news is bad. The gap was filled and now its going to get drilled. Dont be surprised to see NIO in the low 30's on a downgrade.
To learn what PMCB will be doing in their up coming trial just watch the video..
Austrianova (PMCB's partner)will be presenting it’s Cell-in-a-Box and Bac-in-a-Box technologies as one of three chosen participants at the upcoming event "GIA x J-Bridge - Pitching to Japanese Corporates and Investors”, organised by Enterprise Singapore and JETRO (Japan External Trade Organization) on 22nd September 2021
MORE EYES ON PMCB AND CELL IN THE BOX
Thats because junk trades like junk. What does that say nobody thinks its worth the price its at lol. Pink sheet junk thats all this is
Thanks whomever for the shares today I posted the other day I was going shopping for a chunk of shares. It was a perfect spot to buy size. The best thing I wasnt even watching . lol I got the fill when we were playing golf didnt know till 10 mins ago. I never pick up the Phone while playing Shinnecock lol. No phones allowed if its an emergency the caddie master will come out and get you. Have a great weekend the fun has just begun Ill ck back later for the close. Get the IND filed and we have GOLD...
https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=3183&fbclid=IwAR0H8L71r2qWdTe8Z1Qev-VeEuRTTfj4-vdd9OZWdglfKW53cZ95KpB27WM
Laguna Hills-based PharmaCyte Biotech, a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, announced that it had entered into agreements with institutional investors for the purchase and sale of 14 million shares of the company's common stock for gross proceeds of $70 million. PharmaCyte's product candidate for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body.